What question did this study set out to answer?

This research aims to create bispecific miniantibodies by fusing antibody constant domains for enhanced targeting of cancer cells.

January 30, 1998FEBS LettersOpen Access

The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

View Full Paper

Ask AI

Bookmark

This research aims to create bispecific miniantibodies by fusing antibody constant domains for enhanced targeting of cancer cells.
Genetic fusion of C(H)1 domain of IgG1 to scFv-425 specific for EGF receptor.
Fusion of C(L) domain of kappa light chain to scFv-M1 specific for CD2.
Functional expression in E. coli and verification of assembly and binding through immunoblots and SPR biosensor measurements.
Correct assembly and expression of bispecific miniantibodies confirmed through immunoblots and gel filtration analysis.
Fab-to-Fab binding affinity was successfully measured, showing improved functionality compared to traditional bivalent constructs.
Demonstrated potential for application in cancer immunotherapy through bi-specific targeting of EGF-R and CD2.

No takes yet. Share an insight, caveat, or question.

Randomized trial investigates bispecific miniantibodies targeting EGF receptor and CD2, suggesting potential for cancer immunotherapy.

Müller et al. (1998) studied this question.

View Full Paper

Ask AI

Bookmark